|
Gene: TSPAN3 |
Gene summary for TSPAN3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TSPAN3 | Gene ID | 10099 |
Gene name | tetraspanin 3 | |
Gene Alias | TM4-A | |
Cytomap | 15q24.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | O60637 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10099 | TSPAN3 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 9.70e-03 | -3.60e-01 | -0.0809 |
10099 | TSPAN3 | C04 | Human | Oral cavity | OSCC | 3.96e-22 | 1.16e+00 | 0.2633 |
10099 | TSPAN3 | C21 | Human | Oral cavity | OSCC | 2.81e-44 | 1.74e+00 | 0.2678 |
10099 | TSPAN3 | C30 | Human | Oral cavity | OSCC | 6.02e-37 | 1.78e+00 | 0.3055 |
10099 | TSPAN3 | C38 | Human | Oral cavity | OSCC | 6.01e-04 | 6.67e-01 | 0.172 |
10099 | TSPAN3 | C43 | Human | Oral cavity | OSCC | 7.35e-40 | 6.60e-01 | 0.1704 |
10099 | TSPAN3 | C51 | Human | Oral cavity | OSCC | 8.00e-11 | 8.82e-01 | 0.2674 |
10099 | TSPAN3 | C57 | Human | Oral cavity | OSCC | 1.14e-20 | 9.18e-01 | 0.1679 |
10099 | TSPAN3 | C06 | Human | Oral cavity | OSCC | 1.06e-07 | 1.50e+00 | 0.2699 |
10099 | TSPAN3 | C08 | Human | Oral cavity | OSCC | 2.05e-50 | 9.86e-01 | 0.1919 |
10099 | TSPAN3 | C09 | Human | Oral cavity | OSCC | 5.45e-03 | 3.45e-01 | 0.1431 |
10099 | TSPAN3 | LN22 | Human | Oral cavity | OSCC | 2.83e-02 | 8.82e-01 | 0.1733 |
10099 | TSPAN3 | LP15 | Human | Oral cavity | LP | 2.90e-12 | 1.78e+00 | 0.2174 |
10099 | TSPAN3 | EOLP-1 | Human | Oral cavity | EOLP | 3.42e-02 | 8.60e-02 | -0.0202 |
10099 | TSPAN3 | SYSMH1 | Human | Oral cavity | OSCC | 7.20e-28 | 6.72e-01 | 0.1127 |
10099 | TSPAN3 | SYSMH2 | Human | Oral cavity | OSCC | 1.36e-28 | 6.67e-01 | 0.2326 |
10099 | TSPAN3 | SYSMH3 | Human | Oral cavity | OSCC | 4.32e-31 | 7.31e-01 | 0.2442 |
10099 | TSPAN3 | SYSMH4 | Human | Oral cavity | OSCC | 6.61e-05 | 1.38e-01 | 0.1226 |
10099 | TSPAN3 | SYSMH5 | Human | Oral cavity | OSCC | 8.31e-12 | 3.77e-01 | 0.0647 |
10099 | TSPAN3 | SYSMH6 | Human | Oral cavity | OSCC | 9.33e-28 | 7.52e-01 | 0.1275 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007265921 | Liver | HCC | protein localization to plasma membrane | 177/7958 | 284/18723 | 1.02e-11 | 4.18e-10 | 177 |
GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
GO:00469311 | Liver | HCC | pore complex assembly | 17/7958 | 20/18723 | 1.18e-04 | 9.87e-04 | 17 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TSPAN3 | SNV | Missense_Mutation | c.390N>A | p.Asn130Lys | p.N130K | O60637 | protein_coding | deleterious(0.03) | benign(0.142) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
TSPAN3 | SNV | Missense_Mutation | c.239G>A | p.Arg80His | p.R80H | O60637 | protein_coding | tolerated(0.1) | benign(0.12) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TSPAN3 | SNV | Missense_Mutation | rs376931567 | c.238C>T | p.Arg80Cys | p.R80C | O60637 | protein_coding | tolerated(0.16) | benign(0.082) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
TSPAN3 | SNV | Missense_Mutation | rs749142832 | c.748N>A | p.Gly250Arg | p.G250R | O60637 | protein_coding | deleterious_low_confidence(0) | benign(0.312) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TSPAN3 | SNV | Missense_Mutation | novel | c.104T>G | p.Phe35Cys | p.F35C | O60637 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TSPAN3 | SNV | Missense_Mutation | novel | c.353N>A | p.Ser118Asn | p.S118N | O60637 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
TSPAN3 | SNV | Missense_Mutation | c.415G>T | p.Asp139Tyr | p.D139Y | O60637 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TSPAN3 | SNV | Missense_Mutation | rs375306231 | c.350N>A | p.Arg117His | p.R117H | O60637 | protein_coding | tolerated(0.57) | benign(0.005) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TSPAN3 | SNV | Missense_Mutation | c.257T>C | p.Phe86Ser | p.F86S | O60637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TSPAN3 | SNV | Missense_Mutation | c.257N>A | p.Phe86Tyr | p.F86Y | O60637 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-55-1594-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |